活動

Presentations

[Published] 2020/3/18 [Last updated] 2024/6/11

Presentations:AACR 2024

AACR2024
Dr. Yuki Katsuya from our department presented a poster at AACR(American Association for Cancer Research) Annual Meeting 2024.

  • Abstract CT062: A phase 1 study of tamnorzatinib (ONO-7475), an Axl/Mer dual inhibitor, alone and in combination with nivolumab in patients with advanced or metastatic solid tumors

Presentations:ESMO 2023

ESMO2023での
Dr. Ryo Sadachi (Biostatistics Division) and Dr. Mao Okada (Department of Experimental Therapeutics) presented a poster at ESMO (European Society for Medical Oncology) 2023.

  • #1880: Regional differences in drug-induced lung disease (DILD) caused by anticancer drugs between the US, EU and Japan: a large-scale data-based analysis using the FDA Adverse Event Reporting System (FAERS)

Presentations:ASCO 2023


At ASCO(American Society of Clinical Oncology)2023, Dr. Yuji Uehara, who was a resident in our department from April to June 2022, made a poster presentation.

  • Impact of patient travel time on disparities in precision oncology clinical trials. Yuji Uehara, Takafumi Koyama, Yuki Katsuya, Jun Sato, Noboru Yamamoto; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan DOI: 10.1200/JCO.2023.41.16_suppl.3113
  • PDF

Dr. Takafumi Koyama from our department also made a poster presentation.

  • Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004). Takafumi Koyama, Toshio Shimizu, Yuki Kojima, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Tatsunori Shimoi, Hitoshi Ichikawa, Shinji Kohsaka, Akihiko Yoshida, Naoko Matsui, Kenichi Nakamura, Noboru Yamamoto, Kan Yonemori DOI: 10.1200/JCO.2023.41.16_suppl.11544